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AIM / OBJECTIVES: Describe the objectives of your study (maximum 30 words)
The aim of the study was to assess prospectively, the complications following TRUS 
guided prostate biopsy. The primary objective of the study was to assess urosepsis 
requiring hospitalisation. The secondary objective was to assess the incidence of other 
complications following TRUS guided prostate biopsy. These include; fever, hematuria, 
hematochezia, urinary retention and pain or discomfort.
MATERIAL AND METHODS: Explain the clinical and statistical methods used (maximum 100 
words)
All consecutive patients under evaluation of suspected carcinoma prostate were 
included in the study. All patients underwent detailed history and physical examination. 
Standard 12- Core prostate biopsy done. Inclusion Criteria: Raised prostate specific 
antigen (PSA >4.0 ng/ml), abnormal digital rectal examination (DRE) or outside biopsy 
report suggestive of prostate cancer but no slides/blocks available for review. Exclusion 
Criteria: Patients refused to give consent, patients started on prophylactic antibiotics 
two days prior to biopsy.
RESULTS:  Summarise the findings and conclusions of your study (maximum 90 words)
A total of 89 patients underwent TRUS guided prostate biopsy. Fourteen patients were 
excluded from the study as they received oral prophylaxis before prostate biopsy 
regardless of their urine culture report. The remaining seventy five patients were included 
in the study. The mean age of patients was 60.69 years. Diabetes and hypertension were 
the most common associated co-morbid illnesses. Most common presentation was lower 
urinary tract symptoms. Only five patients developed low grade fever. One patient 
developed urosepsis and septic shock after prostate biopsy and was hospitalised. 
Subgroup analysis showed that patients with positive urine cultures had more infection as 
compared to the other group where urine culture was either sterile or contaminants. 
Diabetic patients had more incidence of infection compared to non-diabetics. Ten patients 
were on catheter prior to prostate biopsy. There was no infection noted in this group 
following biopsy. 
CONCLUSIONS:
Trans rectal ultrasound guided prostate needle biopsy is safe for diagnosing prostate 
cancer. The most common complication was hematuria in 26.4% of cases, followed by 
low grade fever. Incidence of sepsis requiring hospitalisation was very low in our study. 
Increased incidence of infection in patients with positive urine culture suggests that 
treatment of infection and documentation of negative urine culture before biopsy may be 
wiser. Positive 7pre-biopsy urine culture and diabetes mellitus are risk factors which 
should be looked into before planning prostate biopsy.
Keywords: Trans rectal ultrasound; Lower urinary tract symptoms; sepsis, prostate 
specific antigen.
Introduction
The most common non-cutaneous cancer in United States is prostate cancer, an 
approximate 241,000 cases diagnosed in 2012. And also, the second most common cause of 
cancer-related death (1). The recommended methods for screening of prostate cancer are 
prostate specific antigen (PSA) test and rectal examination. But prostate needle biopsy is 
necessary to make the diagnosis. Prostate biopsies were originally done with either digitally 
guided or trans-perineal biopsy trucut. But with the development of trans rectal ultrasound, 
all trucut biopsies have been replaced by trans rectal ultrasound (TRUS)-guided prostate 
biopsy (2).
Majority of the prostate biopsy related complications are mild and self-limited but 
sometimes it could be severe and life threatening. Infection, bleeding, and urinary retention 
are the most common complications after prostate biopsy. Among Infectious complications, 
mild fever, febrile UTI, and sepsis are common (3–6). Recently, there is an increase in 
hospitalisation rate due to infectious complication following prostate biopsy (7). Multiple
factors could be responsible for recent trends. Bacterial resistance to fluoroquinolones and 
the lack of standard regimen for antimicrobial prophylaxis before prostate biopsy 
apparently the most common factors (8–11). 
This is a prospective study, designed to evaluate the complications of TRUS guided prostate 
biopsy.
Aims and Objectives
AIMS:
The aim of the study was to assess prospectively, the complications following trans rectal
ultrasound (TRUS) guided prostate biopsy. 
OBJECTIVES:
Primary objective of the study was to assess urosepsis requiring hospitalisation.
Secondary objective was to assess the occurrence of other complications following biopsy of 
prostate. These include-
 Fever 
 Hematuria
 Hematochezia
 Urinary retention
 Pain or discomfort
       
Review of Literature
Historical Perspective:
Prostate biopsy was first described by Ferguson in 1930. He obtained cancer cells by 
aspirating prostate tissue with 18G needle, trans-perineally (12). The first trans rectal core
needle prostate biopsy was performed by Astraldi in 1937 (13). There were various
instruments developed and modifications occurred since then for core needle biopsy. All 
biopsies were done using finger guidance for palpable abnormality of prostate, either trans 
perineal or trans rectal route.
Wild and Reid in 1955, first reported use of trans rectal ultrasound (TRUS) of prostate. It was
popularised by Watanabe et al. in 1970 (14,15). TRUS guided prostate biopsy was started in 
late 1980s using 18 Gauge needle on a spring device (Biopty Gun). Since then it has become 
a standard procedure. The “sextant biopsy” model was proposed by Hodge in 1989 (16). 
Sextant biopsy was standard method for prostate biopsy until Stamey in 1995, suggested 
taking samples from more lateral parts of the prostate to include peripheral zones. Studies 
of radical prostatectomy specimen section analysis had shown that prostate cancer most 
commonly arises from peripheral zones. Therefore laterally directed biopsies were advice to 
increase the yield of cancer detection as well as reduce the missing out  cancer foci (17). 
Thereafter, technological advancement has improved the TRUS and its role in prostate 
cancer detection. Recent advancement in prostate imaging includes Colour Doppler, MR 
spectroscopy, MRI/TRUS fusion analysis and prostate Elastography. They are particularly 
useful in cases where 1st biopsy came as negative but clinical suspicion for prostate 
carcinoma is high. 
Epidemiology of carcinoma prostate:
Incidence of prostate cancer is commonest non skin cancer in U.S. population. The lifetime 
risk of disease is estimated to be approximately 16%, with a 2.5% risk of death. Among U.S. 
population, African-Americans have the highest incidence of carcinoma prostate.
Worldwide, it is the 5th most common cancer and the 2nd second most common among 
men. Overall, incidence of carcinoma prostate was about 12%, 19% in developed countries 
and about 5% in the developing countries. There is a wide variation of incidence among 
countries and ethnicity. Asia has lowest incidence rates and highest among North America 
and Scandinavian population (1,18). Introduction of PSA has led to much increase in 
incidence of prostate cancer. Similar to prostate cancer incidence, there is wide variation in 
mortality among countries. Highest rate of mortality in African countries southeast China, 
Asia and North Africa has lowest mortality (18). The CONCORD study analysed cancer 
survival in different countries and reported different survival rates for colorectal, breast and 
prostate cancer. There was large variation in 5-year survival rates; it was highest in the 
Canada, Australia, and United States and to lowest in Algeria, Poland and Denmark. The 
accuracy of cancer registries, access to health care and quality of health care as well as PSA 
screening affect prostate cancer reporting (19).
In recent period, there have been efforts to diagnose prostate cancer at earlier stage. This 
has resulted in diagnosing increased number of clinically insignificant prostate cancer,
described as small-volume, lower-grade prostate cancer. The 10-yr survival rate was similar 
to general population (20,21). 
Despite screening programme to detect early prostate cancer, a large number of significant 
prostate cancers are still under diagnosed. Under-diagnosis was defined as inability to 
diagnose high grade, high-risk, locally advanced or surgical margins positive, if resected, 
prostate cancer (22). 
Over-detection was defined as detection of small volume prostate cancer, localised with 
Gleason score ≤4 or 5. Studies showed that about 1–7% of patients were over diagnosed
and the resulting into consequent overtreatment. Over-diagnosis of prostate cancer is a 
major concerns in prostate oncology (23).
Role of Prostate Biopsy:
Initially prostate biopsy was used to diagnose prostate cancer. Now it has evolved from not 
only to detect cancer but to assist in clinical management of patient. Prostate biopsy plays 
an important role in active surveillance (AS) programme. Therefore it should be 
reproducible. It has an important role in standardised staging and grading of prostate cancer
(20). 
Historically, sextant biopsy was the standard to diagnose prostate cancer. Studies showed 
that there was increased number of missing clinically significant prostate cancers due to
sampling error while doing sextant biopsy. This has resulted to the introduction of 
extended-core prostate biopsy strategies (24–27).  One study has assessed the role of 
extended biopsy in Gleason stage up gradation. It included 301 patients with low-risk 
prostate, an extended (>or=10-core) prostate biopsy was done. 18 cores of biopsy were taken 
in majority of patients. The up gradation was reported in 31.9% patients (28). 
To detect missed cancer and to assess the tumor volume as well as prognosis, extended or 
saturation prostate biopsies were advised (29).
Risk stratification of prostate cancer: (30)
There are three risk categories described for prostate cancer;
Low risk group: PSA < 10, Gleason score ≤ 6 and stage T1 or T2a. 
Intermediate risk group: PSA 10 - 20, or Gleason score = 7 or stage T2b or T2c.
High risk group: PSA > 20, or Gleason score ≥ 8 or stage T3, or two or more intermediate risk 
factors.
Watanabe was the first to describe trans rectal ultrasonography (TRUS) of the prostate in 
1968, later with technological advancement of ultrasound and use of trans rectal ultrasound 
for prostate biopsy, it was included in routine clinical use (16). Increased numbers of 
patients are undergoing TRUS guided prostate biopsy annually in the United. Prostate 
cancer prevalence is high similarly large number of patients undergoing trans rectal prostate 
biopsy under ultrasound guidance now a days.
Ultrasonography of the Prostate:
The prostate gland is located anterior to rectum between the bladder neck and the 
urogenital diaphragm.
Prostate gland is divided into following zones-
 Anterior fibro muscular stroma (AFS)
 Central zone (CZ)
 Transition zone (TZ)
 Peripheral zone (PZ)
 Periurethral zone
These zones cannot be differentiated on trans rectal ultrasonography (TRUS). Central and 
peripheral zones of the prostate are located posteriorly and appear homogenous on TRUS. 
Most of the adenocarcinoma prostate arises from these regions. Multiple, small and diffuse 
calcifications of the prostate are a normal ultrasonographic finding. It is an age related and 
not a pathological. Prostatic calculi are symptomatic if large, needs further evaluation and
treatment. 
Figure 1
Normal Trans rectal ultrasound image.
A, Transverse view. B, Sagittal view
AFS, anterior fibro muscular stroma;
CZ, central zone; DV, dorsal vein
complex; EJD, ejaculatory ducts; 
TZ, transition zone; U, urethra.
Gray-scale trans rectal ultrasonography (TRUS):
Currently, TRUS is the most common imaging for prostate evaluation. The most common
use of TRUS is for prostate cancer detection, there is other indications also esp. Infertility 
where it can be useful. There are two types of endorectal probes, side-fire and end-fire 
models with 6 to 10 MHz frequencies. The biplane probes give simultaneous transverse as 
well as sagittal views. The resolution of images increases with increase in frequency of 
ultrasound probe. High frequency probes have small focal length and image is very close to 
the transducer. The 7-MHz transducer results in high-resolution image and is best for 
peripheral zone of prostate. Lower frequency probes have large focal length but the 
resolution of images will be low. They are accurate of volume measurements.
Techniques:
Prostate should be evaluated in both transverse as well as sagital planes. Prostate volume is
calculated. Hypo-echoic lesions are looked in central and peripheral zones.
Figure 2
Trans rectal ultrasound image of the prostate.
A, In the transverse 
B, Midline sagittal view.
Patient positioning during TRUS:
Left lateral position is the most preferred position for prostate biopsy. 
Prostate Volume Calculations:
Various formulas are described for calculation of prostate volume. Prostate measurements 
are taken in three dimensions, axial plane, transverse and antero-posterior, to calculate the 
volume. Most commonly used formula is -
 Prolate spheroid (π/6 × transverse diameter2 × antero-posterior diameter). 
Hypo-echoic lesions within peripheral zones should be identified and biopsied. Majority of 
suspected lesions for prostate cancer are hypo-echoic lesions. About 39% of malignancies
are iso-echoic and ~1% of tumors are hyper-echoic on TRUS. Although hypo-echoic lesions 
are most commonly turn out to be prostate cancer, other disease processes like
granulomatous prostatitis, prostatic infarct and lymphoma can also produce hypo-echoic 
lesions. About 17% to 57% of cases, a hypo-echoic lesion is malignant, required to biopsy 
these lesions. Any contour abnormalities along the surface of the gland are suspected to be 
prostate cancer. Extra capsular extension of prostate cancer is noted by loss of bright white 
peri prostatic fat (31).
   
Prostate biopsy under image guidance:
Prostate gland imaging improves cancer detection by precisely visualising and characterising 
the lesion as well as to guide the accurate and targeted biopsy. Currently, with the help of 
newer imaging modalities such as MRI and contrast enhanced TRUS, a higher number of 
image-targeted cancers in suspicious lesions have been found (32–34). These studies have 
shown that targeted biopsies detect cancer of high grade and tumor volume than that of 
conventional TRUS biopsy. Therefore targeted biopsy may be helpful in prostate cancer 
grading, prognosis and deciding treatment.  Recent studies had introduced modern imaging, 
such as elastography. A prospective randomised study showed sensitivity and specificity of 
real-time elastography as 61% and 68% respectively as compared to grey-scale ultrasound
which showed sensitivity and specificity of 15% and 92% respectively (35).
Routine prostate biopsy may be called as image-blinded prostate biopsy. Tumor lesions 
identified on image will result in better yield of malignant tissue than the image-blinded 
Figure 3: Hypo-echoic lesion noted on the 
right lateral aspect of prostate 
procedure. Image localisation of cancer provides precise identification of the cancer, which 
would result in better lesion-targeted management. A systematic review on targeted biopsy 
using image-guided prostate biopsy and MRI localised lesions had shown that cancer was 
detected in 30% of MRI targeted cores versus 7% of systematic cores (36).
Another newer modality of prostate is MR/TRUS image fusion (37). However, Utility of 
MRI/TRUS fusion imaging needs to be validated as the prostate is a deformable organ 
changes its shape during TRUS but it remains the same on MRI (20).
Role of MRI/MR spectroscopy:
Recently, the role of MR spectroscopy and targeted biopsy was assessed. The high 
diagnostic accuracy of magnetic resonance spectroscopic imaging and dynamic contrast-
enhanced imaging magnetic resonance (DCEMR) in the management of prostate cancer was 
evaluated in one study. MRS detects metabolic activity of tissues and can deferntiate 
normal from cancerous tissue based on ratios of creatine, choline and citrate production 
and consumption (38). Cancerous tissue contains less citrate level and higher concentrations 
of choline and creatine when compared with benign prostatic hypertrophy or normal 
prostatic tissue. A randomised controlled trial, recently evaluated the role of MRS and 
dynamic contrast enhanced MR (DCEMR) imaging in cases of prior negative biopsy but high 
suspicion of prostate cancer. The patients with a prior negative prostate biopsy and 
persistently elevated PSA levels, a combination of a standard 10-core biopsy scheme with an 
oversampling strategy in sites targeted by combined MRSI/DCEMR indications resulted in 
significantly higher cancer detection rates. At the second biopsy, a prostate cancer detection 
rate was significantly high among those where MRS/DCEMR technique were utilised (P = 
0.01). The prostate cancer detected with the help of MRS/DCEMR were high grade (Gleason 
score ≥7 (4+3) 61.6%) (39).
Prostate Biopsy Technique:
18 Gauge needle loaded on a spring action device is used for prostate biopsy. When trigger 
button of device is pushed, the inner needle advances 23 mm followed by outer hollow core 
needle. The prostate tissue is caught between inner needle and outer sheath and therefore 
disengaged from the prostate gland. The device is design to obtain 15 mm to 17 mm length 
of the tissue during biopsy. 
Techniques of Extended Core Biopsy:
The sextant biopsy had a low yield of cancer detection therefore sampling of more tissue 
from laterally focused cores are introduced. Various studies have shown improved detection 
rate of cancer by laterally directed biopsy cores in addition to the standard systematic 
sextant technique. Extended core biopsy includes 8 to 13 cores (24,40,41). 6 cores biopsy is 
not adequate for prostate cancer detection. 
Transition zone as well as seminal vesicles is not routinely sampled because of low cancer 
detection rate at initial biopsy. Transition zone biopsy may help in case of large gland (more
than 50 ml). It increases additional 15% chances of cancer detection.
Trans rectal ultrasound guided prostate needle biopsy is the gold standard for diagnosing 
prostate cancer. PSA based screening programs has resulted in detection of early prostate 
cancer. There is a significant increase incidence of organ confined disease and potentially 
curable due to PSA screening (42). Most accepted PSA threshold above which biopsy 
advised is >4.0 ng/ml, although optimal PSA threshold is not yet defined in asymptomatic 
men. As the PSA threshold was lowered to >2.5 ng/ml, it has resulted in increased detection 
of organ confined prostate cancer at the time of radical prostatectomy.
This observation has led to recommendation of prostate biopsy in younger men (below 60 
years if PSA rises above 2.5ng/ml (43). There is no PSA level that can exclude prostate 
cancer in age range as shown in Prostate Cancer Prevention (PCPT) Trial. Thompson and 
colleague in their data showed that men with PSA less than 4.0 ng/ml, large numbers of 
patients were diagnosed as prostate cancer. Prostate cancer was diagnosed in 15% of 
patient with PSA level < 4.0, and there will be 15% of patient having a Gleason score of ≥ 7 
(22).
Figure 4
A, Sextant biopsy B, 10-core biopsy C, 12-core biopsy
D, 13-core or “5-region biopsy” 
To reduce the chances of under-diagnosis of high risk disease, prostate biopsy was 
extensively performed as well as PSA threshold for performing biopsy was also reduced in 
the last decade. This has resulted to increased number of “insignificant cancer” being 
diagnosed. Similarly, there is an increased number of biopsy cores to diagnosed prostate 
cancer.
Urinary tract infection (UTI) or prostatitis may cause false elevation of PSA. Most of the 
cases, PSA value ranges between 2.5–10.0. Guidelines recommend repeating such abnormal 
PSA value before deciding upon performing prostate biopsy (20).
Number of prostate biopsy cores:
Increased numbers of cores and proper localisation of these cores were considered optimal 
to sample entire prostate. Haas et al. did biopsy on prostates of 164 autopsy patients. 18-
core biopsy was performed in all patients. Analysis showed that 12-core specimen detected 
most of cancers which is clinically significant with 80% sensitivity (44). It was found that 
cancer detection was related more to location of samples rather number of biopsy cores 
and samples containing lateral and apical cores were representing the peripheral zone (PZ) 
tissue where prostate cancer mostly occurs.
Initial biopsy:
Currently the 12-core biopsy is widely accepted method of biopsy. Some studies did show 
that taking biopsy cores from apical region on each side improves the yield of detecting 
prostate cancer. Cancer is missed mostly at the apical location during initial biopsy (45). 
Controversy exists regarding number of biopsy cores and age of the patient as well as 
volume of prostate. Extended biopsy has a significant superiority of cancer detection rate 
when compared with sextant biopsy (46). Studies have shown that extended biopsy cores 
>12–14 as initial prostate biopsy scheme has no advantage over standard 12-core biopsy 
(47,48).
Repeat biopsy:
Indications:
 Inadequate prostatic tissue to diagnose or exclude prostate cancer. 
 Previous negative biopsy but persistent clinical or biochemical suspicion for 
carcinoma prostate (e.g. abnormal DRE, persistently raised or rising PSA).
 Previous biopsy of multifocal High Grade PIN and/or Previous Suspicious 
Appearances (ASAP)
Systematic prostate biopsy has the potential to miss small volume prostate cancer in some 
patients. Therefore these patients undergo repeat biopsy. About 30% to 50% of patients 
detected to have cancer on repeat biopsy, mostly with extended biopsy scheme (20).
Scattoni et al. proposed a model for repeat prostate biopsy considering the clinical 
characteristics of the patients. Patients with ASAP, a 14-core biopsy without TZ sampling
were done. A 14-core biopsy with four TZ cores if there is no ASAP but %free PSA was ≤10%. 
If there is no ASAP and %free PSA >10%, a 20-core biopsy including four TZ cores was found 
to be useful (49). 
Ideally, samples should be located at different sites after negative biopsy to identify tumours which
were not sampled in the previous biopsy. In case of multifocal HGPIN or ASAP, repeat biopsy to an 
adjacent sites should be sampled. In about half of the cases of ASAP, cancer is found in the same 
location. There is a risk of carcinoma in the entire gland in case of HGPIN (50,51). The natural 
history of atypical small acinar proliferation (ASAP) is not well defined as compared to 
HGPIN, if ASAP is seen in the biopsy, there is a significant chance of diagnosing prostate 
cancer on repeat biopsy. Current recommendations are to repeat biopsy within 3 to 6 
months in case of ASAP or HGPIN on initial biopsy. The most common areas missed during 
initial biopsy are apices and anterior prostate.
Saturation Biopsy:
Saturation biopsy has been recommended by some investigators to maximise the cancer 
detection rate in patients where the clinical criteria put them at high risk for prostate cancer 
despite a previous benign biopsy. It has been performed with peri prostatic nerve block, 
under sedation or under general or spinal anaesthesia (26,52). The office-based trans rectal 
saturation biopsy technique with biopsy cores of ≥20 has increased the prostate cancer 
diagnosis by 30%. However, complication rate was similar to that  of standard biopsy (53).
Cancer detection rate by saturation biopsy protocol is similar to extended core (10-12 Core) 
biopsy, which is less morbid procedure. Therefore role of saturation biopsy has decreased 
with time.
When serum PSA level is in the range of 4.0 to 10.0 ng/ml, % free PSA less than 25% helps in 
95% chances of detection of prostate cancer and avoids 20% prostate biopsies, and the risk 
of cancer increased further decline of free PSA (42). Similarly, a PSA velocity >0.75 
ng/ml/year has increased suspicion of prostate cancer and suggests biopsy (54). The clinical
utility of PSA velocity is controversial in detecting clinically significant prostate cancer. 
Before deciding on a repeat prostate biopsy to detect suspected prostate cancer, an
elevated PSAD and PSAD-TZ suggests repeat biopsy to diagnosed prostate cancer.
Prostate Biopsy contraindications:(55)
 Significant coagulopathy
 Painful condition 
 Immunosuppression
 Acute prostatitis 
Prophylactic Antibiotics:
There are various prophylactic antibiotic regimens described. American Urological 
Association recommends antibiotic prophylaxis before trans rectal prostate biopsy (56). 
Controversy exits regarding the duration of antibiotics after biopsy. Studies have shown that 
fluoroquinolone prophylactic regimens, single-dose oral is equally effective than 3-day 
regimens to prevent infections (56,57).
Rectal Cleansing Enema prior to Biopsy:
Various strategies reducing infectious complications have been explored. One study by Gil-
Vernet used povidone-iodine for rectal cleansing prior to prostate biopsy and reported 0.2% 
incidence of E. coli epididymitis. Another study using the same protocol also showed similar 
result (58,59). Contrary to these studies, Zaytoun et al. could not find any difference in 
complications using enema (60). Cochrane review has concluded that risk of bacteraemia
was reduced with enema plus antibiotics in comparison to antibiotics only but risk of fever 
or infection was similar (6).
To reduce the infectious complications, several studies have assessed the role of expanding
the antimicrobials, using different techniques for biopsy and rectal swab cultures. Adding 
ciprofloxacin to amoxicillin-clavulanate resulted decreased of infections(61). Adibi et al. 
evaluated the addition of gentamicin to trimethoprim-sulfamethoxazole or ciprofloxacin and 
compared it with the group where gentamicin was not added and noticed decreased rate of 
hospitalization (62). Another study have reported favourable results with addition of
amikacin (63). Ceftriaxone was added to lidocaine during peri-prostatic nerve block in one 
study, resulted in decreased incidence of sepsis (64). Drawbacks of broad spectrum 
prophylaxis are increased adverse effects, potential increase in antimicrobial resistance and
cost. However, the expenses of hospitalisation increases significantly if admission is required
due to post biopsy infection rather using more intensive prophylaxis prior to biopsy and it is
more cost effective. There is another concept of targeted prophylaxis under investigation. A 
culture swab from rectum is taken and is plated on agar. Patients’ ciprofloxacin sensitive
rectal swab cultures can receive the same as prophylaxis; others to get alternate antibiotics. 
Positive swab culture from rectum is considered as risk factor for prostate biopsy related
infection but it does not always lead to clinical infection. Several prevalence studies have 
shown that approximately 25% of rectal swab cultures contain fluoroquinolone-resistant 
organisms but actual clinical infection occurs in a very small number of these patients (11).
There are no randomized control trials to show that targeted prophylaxis decreases the 
chances infection and expenditure when compared with routine prophylaxis.
There are studies showed that technical modifications had influenced the incidence of 
infection. Trans perineal approach has been suggested as an alternative technique for 
prostate biopsy as it bypasses the rectum which is the source of bacterial contamination and 
subsequent infection. Although it did not result in reduction of infection (65). Size of needle 
or cleaning the needle with iodine solution is not associated with infectious risk. There are 
conflicting reports regarding infectious risk while using same needle in subsequent patients 
or new needle each time for biopsy. However, adequate reprocessing/disinfection of biopsy 
probes and needle guide are of paramount importance. General recommendations for 
assessment of patient prior to prostate biopsy include a complete evaluation including
history and examination and risk factor assessment for bacterial resistant and infectious 
complications (66).
Risk factors for infectious complications:(66)
Patient-related:
 Co morbidities; Diabetes, COPD 
 Heart valve
 Benign prostate enlargement 
 Recent UTI
 Recent antibiotics usage, particularly fluoroquinolone
 Hospitalisation in the recent past
 Indwelling urethral catheter 
 Pre biopsy urine culture positivity  
Procedure-related:
 Increase number of biopsy cores 
 Repeat biopsy 
 Contaminated ultrasound gel
Infection following TRUS biopsy:
Infection following TRUS guided prostate biopsy is a well-established risk, therefore 
evidence supporting antimicrobial prophylaxis. Regarding use of prophylactic antibiotics, a
Cochrane review has reported significant reduction of bacteriuria, bacteraemia, incidence of 
fever, urinary tract infection (UTI), and rate of hospitalisation (6). American Urological 
Association recommends routine antimicrobial prophylaxis for TRUS-biopsy. Majority of 
centres use prophylactic antibiotic prior to prostate biopsy however, there was a wide 
variation among studies regarding duration of antimicrobial use, many of these studies did 
not show significant benefit if used for >24 hours period (67–70).
Incidence of infection and related complications:
Infection rate varied in different studies, with reported rate of hospitalization range from 0–
6.3% (71,72). One study on infection have reported, incidence of UTI in about 3.5% patients 
and 3% required hospitalisation after biopsy. Simsir et al showed similar incidence of 
septicaemia (73,74). Contrary to them, other studies had shown decreased incidence of 
sepsis (0.6% to 1.7%) following prostate biopsy (60). Recently, there is an increase incidence 
of antimicrobial resistance particularly fluoroquinolone. Data from US SEER–Medicare
showed a 2 fold increase in hospitalization rate for infectious complication as compared to 
controls (7). The risk of sepsis is similar between the first and subsequent biopsies (74).
There was an increased incidence of infectious complications following TRUS-Biopsy 
between 1996 and 2005. There was an increased hospital admission from 1.0% to 4% in this 
duration and about 70% were related to sepsis (75). There was a significant increase in 
hospital admission following prostate biopsy during 1993 to 2010. Majority of infection 
related complications resulted from E coli, with increased resistance to fluoroquinolone, 
ampicillin and sulfamethoxazole- trimethoprim (76).
Bleeding following Prostate biopsy:
Bleeding following TRUS-Biopsy is one of the most common complication which bothers 
patient significantly. These include hematuria, hematospermia, and hematochezia or rectal 
bleeding. Factors responsible for these complications are size of prostate gland, 
anticoagulation drugs, and number of biopsy cores.
Hematuria:
Hematuria is common after prostate biopsy, with incidence of 10–84% (71,75,77). This wide 
range is because of different definitions for hematuria (blood seen in urine, requirement of 
catheterisation or need for hospitalisation) and duration. One study has reported incidence 
of hematuria as 65.8% base on questionnaires, in majority of patients it did not bother to 
them (only about 6% patient considered it as a major problem) (77). Hematuria for >3days
days was reported in about 23% of patients. Incidence was more in case of large prostate
size (78)(60). Increased risk of bleeding as the number of cores increase during prostate 
biopsy is controversial. Ghani and colleague performed biopsy in 760 men and found no 
difference in the prevalence of hematuria and number of biopsy cores (79). Another study
showed increased chances of bleeding as the number of biopsy core increased (80). Prostate 
biopsy needle size does not affect bleeding rates. Hospital admission following prostate 
biopsy was reported as 1.4% within 30 d, out of which 20% were related to bleeding (75). 
Gross hematuria requiring catheterization following biopsy was noted in 0.4% of patients, 
bleeding requiring admission in 0.14% patient (81). Mild hematuria is commonly noticed 
after biopsy but it is very rare to have significant bleeding which require hospitalisation
(<1% incidence) (66).
Hematochezia or Rectal bleeding:
Incidence of hematochezia is ranging from 1.3% and 45% (71). The various studies have 
reported increasing rate of bleeding with extended prostate biopsy and patients on 
anticoagulation but it was not related to size of prostate biopsy needle (79,82). In majority 
of cases, rectal bleeding was common (36.8%), but it was a major problem in only 2.5% 
cases (77). Patients who are counselled properly regarding rectal bleeding and hematuria, it 
is of little consequence. It is very rare to notice massive rectal bleeding following prostate 
biopsy and it could be fatal. There are various treatment alternatives available to control 
rectal bleeding like balloon tamponade, injection of adrenaline endoscopically, 
sclerotherapy or endoscopic direct vessel clipping (83–86). 
Hematospermia:
Varied incidence of hematospermia reported in literature (1.1–93%) (87). This could be 
related cultural issues, varied perceptions or social stigma. One study reported almost all 
patient had hematospermia (92.6%). This is an alarming 25% of men (77). Post prostate 
biopsy, there was a gradual decline in hematospermia over time. There was an anxiety and 
decreased sexual activity with hematospermia which improved subsiquently. ERSPC study
showed hematospermia in about 50% patient and it was found that incidence of 
hematospermia is related to age, prostate volume, and history of TUR of prostate (78). As 
the number of biopsy core increases the incidence of hematospermia also increases.
Anticoagulation:
Discontinuation of anticoagulation prior to biopsy is a very critical issue and it has to be 
looked at thoughtfully. There is cardiovascular risk when anticoagulation is stopped while a
bleeding risk and associated complications with continuation of these drugs. There are
factors which modify the balance of risks and benefits. Giannarini and colleague assessed 
the role of aspirin continuation before prostate biopsy and evaluated 196 men, divided 
them into three groups, aspirin group, aspirin replaced with LMWH or no aspirin group. All 
three groups did not show any difference in bleeding rate (p = 0.26). However, there was 
prolonged duration of bleeding for men on anticoagulation. This study showed that aspirin 
prolongs duration of bleeding but it did not increase bleeding risk (88). It is safe to perform 
prostate biopsy without discontinuing aspirin as the risk of bleeding is very low; however, 
same conclusion can be drawn for warfarin and clopidogrel as there are very few studies 
had looked into it. 
Pain after TRUS biopsy of Prostate:
For TRUS biopsy prostate, analgesia was not always routinely used. However, it causes
significant pain and discomfort as well as anxiety. Increased pain was reported as reluctance 
to second biopsy, if required (77).
Measures of pain:
Visual analogue scale (VAS; 0 = none and 10 = worst pain) is the most commonly used 
measure to assessed pain. Other method is a five-point scale . When using VAS to assess the 
pain, it is considered clinically meaningful if VAS >2 points.(66)
Pain management related to biopsy of Prostate:
There are numerous factors which can contribute to pain during biopsy; anxiety is the main 
concern, which may be greater in young patients. Size of the needle does not affect the 
severity of pain (82). There are other factors affecting pain during biopsy like compliance of 
rectum, volume of prostate and biopsy cores (88). Left lateral decubitus position during 
biopsy was found to have slightly less pain, although it did not reach statistical significance.
Sedo analgesia prior to prostate biopsy has been described. Although very effective, it is 
difficult for use as outpatient, and it also need monitoring of patient post biopsy with 
significant increase of expenditure. However, it remains a viable option for select patient. 
Peri prostatic nerve blockade (PPNB) is a safe procedure, and 20 cc of Lignocain significantly 
reduces pain. Various techniques have been described for PPNB; infiltration to the apex, 
infiltrating the basal region and combined techniques. One study has assessed peri
operative difficulty if any in those patients who received nerve block during biopsy and do
not found any significant difference in operability in those in whom PPNB was given (89). 
Intra rectal creams, gels, and lidocaine suppositories are described to reduce the pain during 
biopsy. These agents found to be more effective when compared with placebo but most 
studies found them to be inferior compared to PPNB (90). 
Figure 5: Ultrasound image of the anaesthetic 
injection site during peri- prostatic nerve bundle 
block. Arrow indicates the site of lidocaine
injection. P; Prostate
LUTS and retention of urine after biopsy:
Risk of urinary retention is very low following prostate biopsy. The incidence reported in 
literature is 0.2% to 1.7% (60,81,3). Number of cores taken during biopsy has no correlation 
with incidence of retention of urine (3). Raaijmakers and colleague have noted certain 
factors which are directly linked to retention of urine, includes volume of prostate, ratio of 
transition zone to total prostate volume and a higher IPSS score (60,78). Affect of α-blockers 
on the incidence of urinary retention following prostate biopsy have been studied. 66 
patients were randomized to Tamsulosin versus no Tamsulosin in a prospective study. There 
was an increased flow rate & significant improvement in IPSS noted in the Tamsulosin 
group. Overall risk of retention is low (<2%). About >25% patients had deterioration of lower 
urinary tract symptoms after biopsy for a brief period, even though it is not always 
recommended to use alpha blocker for majority of patients (91). 
Mortality following Prostate biopsy:
Overall, there is a very low risk of mortality following prostate biopsy. A Canadian 
population based study (N=75,190) showed 0.09% mortality following prostate biopsy (75). 
An analysis of SEER data (N=17,472) suggested mortality rate as 0.31% (7). Hospital 
admission due to infectious complication following prostate biopsy play a significant role 
mortality.
Materials
and
Methods
Design and duration of study:
A prospective observational study design carried out at our institute from September 2013 
to March 2014.
Approval of Institutional Review Board and Ethics Committee was obtained. The IRB no.8452
Inclusion Criteria:
 Raised serum prostate specific antigen (PSA  >4.0 ng/ml)       or
 Abnormal digital rectal examination (DRE)    or
 Both   
 Outside biopsy report suggestive of prostate cancer but no slides/blocks available for 
review
Exclusion Criteria:
 Patients refused to give consent
 Patients started on  prophylactic antibiotics two days prior to biopsy 
All consecutive patients under evaluation of suspected carcinoma prostate were included in 
the study. All patients underwent detailed history and physical examination. Co-morbidities 
were assessed if any, especially diabetes mellitus. Detailed medication history including 
steroid, insulin, anti-coagulation medication, anti platelet drugs was taken. If patient was on 
Warfarin, it was decided to change to either unfractionated heparin (UFH) or low molecular 
weight heparin (LMWH) with an appropriate time of bridge therapy before proceeding for 
prostate biopsy. Similarly, if patient was taking antiplatelet drug like Clopidogrel, it was 
planned to discontinue for 7 days at least prior to biopsy. 
All patients were asked to give urine sample for culture & sensitivity on prior visit. If urine 
culture was negative, single dose of Inj. Amikacin 15mg/Kg IV was given just before doing 
biopsy. But if culture was positive, patients received antibiotics for 3days prior to biopsy and 
were continued for total of 7 days according to sensitivity. 
An information sheet was provided to all patients and those who consented to take part,
were included in the study.
Peri prostatic nerve block was given to all patients before TRUS guided prostate biopsy. 5ml 
of Injection Lignocain 2% (v/v) mixed with 5ml of normal saline and injected 5ml each on 
both sides. 22 gauge 17cm long spinal needle was used for this purpose.
Standard 12- Core prostate biopsy done in each patient and samples were labelled properly 
according to site and side of the prostate and sent for pathology.
Figure 6: Biopsy locations in a 12-core biopsy
Image courtesy- EAUN prostate biopsy guidelines 2011
Ultrasound machine (B K Medical system) model Flexi focus 200 was utilised for prostate 
imaging and to guide prostate biopsy. The ultrasound probe (rectal) model 8808e was a 
7.5MHz biplane probe with slot for TRUS biopsy needle.                       
                                   
Figure 7: Ultrasonography Machine (Courtesy- B K Medical system) model Flexi focus 200 and 
Trans rectal probe
Fig 8: 18 Gauge prostate needle biopsy gun. Courtesy- BARD
Outcomes: 
Primary outcome was to assess urosepsis requiring hospitalisation.
Secondary outcome was to assess the incidence of other complications following TRUS 
guided prostate biopsy. These include-
 Fever 
 Hematuria
 Hematochezia
 Urinary retention
 Pain or discomfort
All patients’ data including follow up, up to 30 days, were prospectively recorded, including 
duration of hospitalisation including intensive care unit (ICU), if required. 
Outcome Definitions:
 Sepsis: SIRS with documented or clinically high suspicion of infection (SIRS includes -  
temperature ≥ 38 C˚ or < 36 C˚; heart rate > 90 beats/minute; respiratory rate > 20 
breaths/minute or respiratory alkalosis; WBC > 12,000 or < 4000 or immature forms >  10%
in case of normal range of total WBC) (6)
 Infection – Any fever post biopsy more than 37.5 C˚
 Gross hematuria – Visible blood in urine
 Hematochezia – Blood noticed in stool
 Urinary retention – Unable to pass urine after biopsy
 Pain or discomfort – Assessed with visual analogue scale 
Sample size calculation:
A target sample size of 95 was calculated using a precision of 4% and 90% desired confidence
level for the infection related complications. This was carried out assuming an average incidence 
of infection related complication of up to 6%. This incidence was arrived at after a 
comprehensive literature review for this statistics.
n= 4 p x q
    d2
p = 0.06
q= 1-p = 0.94
d= 0.004
Statistical analysis:
Statistical analysis was performed using Statistical Package for Social Sciences (SPSS®) 
version 18 (IBM Corporation, USA). 
Frequencies and percentages are used represent the categorical variables. eg; age, prostate 
volume etc.
Descriptive statistics are used to represent continuous variables, eg; mean standard 
deviation.
Chi square test and Fisher’s exact test were used to find the relationship between two 
variables.
p value < 0.05 was considered as statistically significant.
The results are represented graphically using Bar charts and tables.
Results
A total of 89 patients underwent TRUS guided prostate biopsy for suspected carcinoma 
prostate on the basis of raised PSA or abnormal rectal examination during study period. 
Fourteen patients were excluded from the study as they received oral prophylaxis before 
prostate biopsy regardless of their urine culture report. The remaining seventy five patients 
were included in the study.
The demographic characteristics of the patients are given in Table 1. The mean age of 
patients was 60.69 years. Diabetes and hypertension were the most common associated co-
morbid illnesses, being seen in over 58% of the patients. Some of these patients had both 
diabetes mellitus as well as hypertension as co-morbidities.
Table 1  Demographic characteristic (n=75)
Age (yrs)(SD)             60.69 (9.57)
Prostate size (cc) (SD)             24.07 (13.29)
PSA (ng/ml)            96.75 
Co- morbidity
 DM
 HT
 CAD
 COPD
 Post CVA
 CKD
             18
             26
             01
             02
            02
             01
Clinical Presentation:
Most common presentation of these patients was lower urinary tract symptoms. During 
evaluation, they were suspected to have prostate cancer either an abnormal rectal finding 
or raised PSA. At our institution, we do not do screening for prostate cancer. Therefore the 
number biopsies performed during the study period was quit small as compared to any 
other studies where they do routine screening for prostate cancer. Some patients have 
more than one clinical presentations eg; having LUTS and came with a report of raised PSA 
(done elsewhere). Similarly, bone pain with LUTS was another common presentation.
Details of clinical presentation are given in Table 2
Table 2   Presentation
LUTS 53
On catheter for retention of urine 10
Hematuria 3
Raised PSA (on screening elsewhere) 16
Bone pain 6
Abnormal rectal examination 62
Pathological Features of Prostate Biopsy:
Among all the patients who underwent TRUS guided prostate biopsy, only 38 patients were 
diagnosed as adenocarcinoma prostate rest of them did not show evidence of malignancy 
on biopsy tissue. Majority of non-malignant pathology specimen were reported as focal mild 
inflammation or chronic prostatitis. One patient’s biopsy was reported as granulomatous 
prostatitis suggestive of Tuberculosis. He had other features suggestive of urinary 
Tuberculosis. 
Majority of cases had higher Gleason’s score on biopsy. 63% of patients had Gleason’s score 
>7 and peri-neural invasion was seen in more than 81% of patients. Table 3 shows details of 
pathological features of prostate biopsy.
Table 3 Pathological features of Prostate biopsy
Adenocarcinoma prostate 39 (52%)
Gleason score
 >7
 7
 3+4=7
 4+3=7
 <7
24 (61%)
7 (18%)
6 (15%)
2 (5%)
Peri-neural invasion 31 (81.58%)
Tumor volume (mean) 56.45%
Number of positive cores 10.82
Patients who were diagnosed as adenocarcinoma prostate on TRUS biopsy or presented 
with bony pain underwent bone scan. Total of 38 patients had undergone bone scan, out of 
which only seventeen patients did show evidence of osseous metastasis.
Pain during Prostate Biopsy:
Pain during TRUS biopsy prostate was minimal in majority of patients. On visual analogue 
scale (VAS), it was 2 or less in 84% patients as shown in Table 4   
Table 4  Visual analogue scale VAS (n=75)
2 or less 63 (84%)
more than 2 12 (16%)
Complications following Prostate Biopsy:
Only five patients developed low grade fever after biopsy which subsided with antipyretics. 
None of them required hospital admission. Out of these 5 patients, two patient’s pre biopsy 
urine culture was positive, two had sterile culture and one had contaminants in urine 
sample. Those two patients in whom urine samples were positive, they received appropriate 
duration of antibiotics before and after procedure according to culture sensitivity.
Another 71 years of age gentleman with multiple co-morbidities, developed urosepsis and 
septic shock after prostate biopsy. His pre-biopsy urine sample grew two organisms for 
which he was on antibiotics for 3days according to sensitivity pattern. Despite of this,
patient developed features suggestive of sepsis and was hospitalised. The antibiotic was 
upgraded as the patient’s condition deteriorating. He was kept in ICU for 2 days. The urine 
and blood culture sent before upgrading the antibiotic did not grow any organism. Total 
duration of hospitalization was 12 days.
Twenty patients noticed mild hematuria post biopsy which settled in one or two days. Only 
two patients had several episodes of gross hematuria lasted for more than 2 days which 
ultimately resolved on its own. None of them required catheterization or bladder wash. 
Two patients were catheterised after prostate biopsy as they were having overflow 
incontinence. One patient was catheterised post biopsy due to sepsis. None of the patient 
developed urinary retention following prostate biopsy.
Six patients noticed blood in stool after biopsy which settled on its own.
Incidence of hematospermia after prostate biopsy was not assessed in this study
population. Table 5 summarizes the complications of Prostate biopsy.
Table 5     Complications following prostate biopsy (n= 34)
Minor Complications
 Low grade fever
 Hematuria < 2 days
 Hematochezia
5     (6.7%)
20   (26.4%)
6     (8%)
Major Complications
 Sepsis
 Hematuria > 2 days
 Urinary retention
1      (1.3%)
2      (2.7%)
0       
Among all the patients, 20 of them had positive urine culture. 
urethral catheter. E. coli was the most common organism found. Most of these urine 
samples grew single organism. Five urine samples grew 2 organisms and one sample grew 
three organisms. Most of these multiple organism urine samples were from patients who 
were on per urethral catheter. 
were shown in Figure 9
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         Figure 9:  Showing complications following Prostate biopsy 
Five of them were on per 
Pattern of micro-organisms seen on urine culture samples 
no. of patients
Antimicrobial resistance pattern among positive urine culture samples:
There were twenty patients in whom pre-biopsy urine culture was positive. Urinary 
organisms were found resistant to one or more of the eight most common antimicrobial 
agents used. Organisms were most frequently resistant to Cefpodoxime in our study. Seven
patients’ cultures were resistant to Co-trimoxazole and Nitrofurantoin. Only three urine 
culture samples were resistant to Ciprofloxacin. Reason for apparently low resistance to 
Ciprofloxacin was because sensitivity for this antimicrobial was not checked in 70% of urine 
samples. See figure 10 for detail below.
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Figure 10: Positive urine culture samples, showing different organisms 
Subgroup Analysis:
Relationship of Urine Culture with 
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          Figure 11: Antimicrobial r
Table 6: Relationship of urine culture with infection
Infection:
Rate of infection (%)
4/20 (20.0%)
2/55 (3.6%)
4 6 8 10
esistance patterns of pre biopsy urine cultures
p Value
12
0.040
As shown in Table 6, patients with positive urine cultures had more infection as compared 
to the other group where urine culture was either no growth or contaminants. There was a 
statistically significant association of positive urine culture with rate of infection.
Relationship of Urine Culture with Hematuria:
Urine Culture Incidence of hematuria p Value
Positive 6/20 (30.0%)           
                     0.939
No growth or contaminants 16/55 (29.1%)
In both groups almost equal number of patients had hematuria. There was no association 
found between urine culture and incidence of hematuria. See Table 7
Risk of infection in diabetic patients:
Diabetes mellitus Incidence of infection (%) p Value
Present 2/18 (11.1%)            
0.626
Absent 4/57 (7.0%)
      Table 7: Relationship of Urine culture with hematuria
                      Table 8: Risk of infection in diabetics
In our study, it was found that diabetic patients had more incidence of infection compared
to non-diabetics. But the association of diabetes and incidence of infection did not reach to 
a statistical significance as shown in Table 8. 
Association of Infection with indwelling urethral catheter:
Per urethral catheter Rate of Infection (%) p value
Catheter 0/10 (0%)
1.000
No catheter 6/65 (9.2%)
In our study, ten patients were on catheter prior to prostate biopsy. There was no infection 
noted in this group following biopsy. Six patients in non catheter group had infection (9.2%). 
This increase incidence of infection in no catheter group did not reach statistical significance 
(p = 1.000). Table 9
              Table 9: Risk of infection with indwelling catheter
                                 
Discussion
Trans rectal ultrasound guided prostate biopsy has remained the gold standard to diagnose 
prostate cancer. Biopsy related complications are not uncommon. Majority of the 
complications are mild and self-limited but sometimes it could be severe and life 
threatening. Infection and bleeding from urethra and rectum are the most common 
complications following prostate biopsy. Some recent studies have reported increasing 
trends of hospitalisation following prostate biopsy due to infection related complications.
To reduce the incidence of infection following biopsy, there were many prophylactic 
regimens including oral as well as intravenous antibiotics recommended by various studies
(56,57). In our study, one dose of intravenous Injection Amikacin 15mg/kg was given just 
before TRUS biopsy in those in whom urine culture showed no growth or contaminants. 
Otherwise patients received 3 days of antibiotic course before biopsy and continued for 
total of seven days according to culture and sensitivity.
Rectal cleansing with povidone-iodine and enema plus antibiotics has been explored by 
various studies with controversial conclusions. Some studies say that it reduces infectious 
complications but few of them conclude no difference in complications (58–60).  However, 
Cochrane review has concluded that risk of bacteraemia was reduced with enema plus 
antibiotics when compared with antibiotics alone but risk of fever or infection was similar in 
both groups(6). We have not used any kind of rectal cleansing or enema before prostate 
biopsy.
Loeb S et al have identified various risk factors for infectious complications. These include; 
Co-morbidities like Diabetes, COPD, Heart valve, benign prostate enlargement , recent 
urogenital infection, Recent antibiotics, hospitalization, presence of a catheter, positive pre 
biopsy urine culture etc. (66) In our study , the risk factors identified were Diabetes mellitus, 
COPD, per urethral catheter and positive urine cultures. 
Prophylactic antibiotic before prostate biopsy is being used by all centres but the particular 
antibiotic, dose and duration varies widely among centres. However, most studies showed 
no significant benefit if duration is more than 24hours (67,69,70). At our centre, we utilised 
single dose of intravenous Injection Amikacin just before biopsy.
Febrile UTI following prostate biopsy is common. Reported incidence rate of infection in 
different studies is around 3% (73,74). In our study, only one patient had febrile UTI which 
progressed to sepsis and required hospitalisation despite of being on antibiotics prior to 
procedure.
Incidence of fever reported in literature is about 3% to 3.5% (78,92). Our study had reported 
fever in 6% of patient, higher than reported in previous studies.
Hospitalisation rate in our study was 1.3% similar to other studies in which it was 0.6% to 
1.7% (60). But other studies have reported incidence of hospitalisation of 3.1% to 3.06% (73)
Another study reported increase in hospitalisation rate from 1% to 4.1% from 1996 to 2005 
(75)
Hematuria is very common complaint following TRUS biopsy of prostate. Its incidence varies 
in literature from 10-84% (71,75,77). There are various definitions of hematuria in different 
studies (visible blood, need for catheterisation or hospitalisation, also duration of 
hematuria). In a cohort study, incidence of hematuria was reported as 65.8%, but 
bothersome hematuria was only 6.2% (77). Our study reported hematuria in 26.4% patients. 
But bothersome hematuria which lasted for more than 2 days was noted in only 2.7%
patients. None of these patients required any intervention and it subsided on its own. A 
large prospective study on prostate cancer screening had reported prolonged hematuria (>3 
days) in 22.6% and it was correlated with prostate volume (78). We could not assess this 
association in our study population as the number patient in our study was quit small as 
compared to ERSPC study where approximately 6000 persons participated. There are 
studies which had evaluated relationship of hematuria with number of biopsy cores, size of 
the biopsy needle etc. and showed conflicting results. We did not evaluate these factors in 
present study. 
Incidence of hematochezia ranged from 1.3% and 45%. Studies had shown that incidence of 
bleeding increases with increased number of prostate biopsy cores and anticoagulative 
drugs (79).Our study did show incidence of rectal bleeding around 8%. A very low incidence 
rate as compared to previously reported in various studies. This could be due to smaller 
needle size used for biopsy and proper patient evaluation before biopsy. In most of the 
cases of rectal bleeding, if patients are counselled properly regarding rectal bleeding and 
hematuria, it is of little consequence. It is very rare to see massive rectal bleeding and could 
be fatal. No such massive hematochezia noted in our study. Rectal bleeding was noted in 
few patients in our study but it was self limiting.
Hematospermia was noted in almost all studies following prostate biopsy. Its incidence 
varied from as low as 1% to as high as 93% (87). Gradually it declined over several weeks. 
Studies have reported anxiety and reduced sexual activity associated with hematospermia 
which resolved after about eight ejaculations. ERSPC study showed hematospermia in 50.4% 
(78). Our study population included majority of patients above 60 years of age. And almost 
all of them did not have intercourse for a long time, either because of decreased libido or 
due to other socio-economic reasons. 
TRUS guided prostate biopsy causes significant amount of pain. Therefore some form of 
analgesia is mandatory now. One study noted that TRUS biopsy prostate was associated 
with significant pain and discomfort as well as anxiety. This has resulted in reluctance to 
subsequent biopsy, among those it was required (77). There are other factors affecting pain 
during biopsy like rectal compliance, volume of prostate and number of prostate biopsy 
cores. Left lateral decubitus position during biopsy was found to have slightly less pain, 
although the difference may not be clinically significant. Various types of 
anaesthesia/analgesia were described for prostate biopsy. Among them, peri prostatic 
nerve block (PPNB) is safe and effective procedure. We performed prostate biopsy in left 
lateral decubitus position and injected 2% Lignocain 5ml diluted with 5ml of normal saline as 
PPNB. It was very effective in reducing pain during biopsy and majority of our patients (84%) 
did not have clinically significant pain (based on VAS ≤2).
Risk of urinary retention following TRUS-Biopsy prostate is very small (0.2% to 1.7%). 
Number of cores taken during biopsy has no correlation with incidence of retention of urine. 
One study had assessed factors directly linked to retention of urine, includes volume of 
prostate, ratio of transition zone to total prostate volume and a higher IPSS score (78,81,3). 
In our study, no patient had retention following prostate biopsy. There were two patients 
with overflow incontinence and therefore were catheterised after prostate biopsy.
Overall, the risk of mortality is very low following prostate biopsy. Some studies have 
reported it less than 1% (7,75). There was no death in our study.
The subgroup analysis of our study showed that patients with positive urine cultures had 
increased rate of infection compared to other group with sterile urine culture or 
contaminants. It was statistically significant. Increased rate of infection among culture 
positive patients is self explanatory. However, all such patients received a course of 
antibiotics according to culture and sensitivity, started on 3 days prior to biopsy and then 
continued for 5 -7 days. Observation from this study suggests that it would have been ideal
to complete the course of antibiotic and document a sterile urine culture before proceeding 
for biopsy.
Another important correlation was made between diabetes and incidence of infection. 
Although it was not statistically significant, but it was noticed that in diabetic patients 
incidence of infection was higher. It is a well established risk factor for increase incidence of 
infection after biopsy (74,93,94). 
Patients with indwelling urethral catheter prior to biopsy had low incidence of infection
when compared with other group who were voiding, although it was not statistically 
significant in this study. It could be explained as some of the patients who were voiding but 
had significant post void residue and that could have contributed to increased incidence of 
infection. Unlike them, patients who were on urethral catheter, had a decompressed system 
and hence less to develop infection system. However, indwelling catheter itself leads to 
colonisation of bacteria and that may cause infection following any urological procedure.  
Results of various publications on complication of biopsy are shown in Table 10. Caution 
must be exercised during comparisons with other studies due to differences in population, 
sample size, biopsy core, and different definitions of complication as well as follow-up. The 
incidences of hematuria and hospital admission rates are comparable with published 
studies. Incidence of fever was higher in our study. Thorsten H. Ecke et al had very low rate 
of gross hematuria (6.5%). This could be because their definition of gross hematuria was 
including only those who complained of persistent gross hematuria of more than 2 weeks 
after biopsy (95). 
Table 10  Review of recently published studies
Investigator Year No. Biopsy 
cores
Enema AB Fever
(%)
Hosp
(%)
Hemat
uria
(%)
Retent
ion (%)
Djavan 2001 1015 8 NA Yes 3.0 NA 15.9 2.6
Raaijmakers 2001 5802 6-7 No Yes 3.5 0.5 22.6 0.4
Thorsten  H. 2008 336 12 Yes Yes 1.8 0.6 6.5 0.3
Present study 2014 75 12 No Yes 6.7 1.3 26.4 0
AB = antibiotics; hosp = hospitalization; NA = not available
Conclusion
Trans rectal ultrasound guided prostate needle biopsy is safe for diagnosing prostate cancer.
The most common complication was hematuria in 26.4% of cases, followed by low grade 
fever. Incidence of sepsis requiring hospitalisation was very low in our study. Increased 
incidence of infection in patients with positive urine culture suggests that treatment of 
infection and documentation of negative urine culture before biopsy may be wiser. Positive 
7pre-biopsy urine culture and diabetes mellitus are risk factors which should be looked into 
before planning prostate biopsy. 
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Annexure
PATIENT PROFORMA
   To Evaluate the Complications of TRUS guided Prostate Biopsy
  Study number:  
Patient name:                      Hospital no:
Age:
Address:
Presenting complaint: LUTS O/E: Abnormal DRE -
Raised PSA
Miscellaneous
Uroflow-PVR:
PSA level: 1) [T]     [F]    
Urine C/S: Urine microscopy:
If culture positive, which antibiotic and duration?
Symptoms of UTI: Antibiotics used:
If yes, which antibiotic?
Is patient on catheter?
Co-morbid illness: 
Diabetes
Hypertension
Coronary artery disease
Medication use:
Steroid use
DM: OHA Insulin 
Anticoagulation: 
Aspirin - Clopidogrel - Warfarin -
Bone scan:  Done/not done         Metastatic/Non metastatic
TRUS volume of prostate:
Biopsy features:
No. of cores -
No of positive cores – Gleason score – Tumor volume –
Perineural invasion - Lymphovascular invasion - Misc. –
Pain score – VAS (Visual analogue scale):
                     0                                                                                                10
0     No pain
10   Intolerable pain
Complications:
– Infection including sepsis
– Gross hematuria
– Bleeding per rectum
– Hematospermia
– Acute urinary retention
– Hospital admission
Hospital admission –
No. of days –
Need for ICU care -   Yes No
Blood culture-
Urine culture-
Antibiotics
Christian Medical College, Vellore
Department of Urology
To Evaluate the complications of TRUS guided prostate biopsy
Information sheet
You are being requested to participate in a study to evaluate the complications of TRUS 
biopsy of prostate. 
You are suspected to have prostate cancer. And planned to undergo ultrasound guided
prostate biopsy. The procedure will be done under local anaesthesia. Under ultrasound 
guidance, prostate biopsy will be done through anal passage. 
The procedure has certain risks. These include blood in urine, urinary infection, blood in 
stool, unable to pass urine and very uncommonly, severe infection .
If you take part what will you have to do?
If you agree to participate in this study, you will undergo prostate biopsy after giving 
antibiotics (Inj. Amikacin 15mg/kg IV single dose) or culture specific antibiotic course for 
3days if urine culture is positive.  You will be interviewed at the next visit to outpatient 
(about a week) regarding procedure related complications. 
All other treatments that you are already on, will be continued except Warfarin or 
Clopidrogel. Clopidrogel to be discontinued for min. of 7days and Warfarin to be changed to 
heparin or other appropriate drug.
If at any time you experience any problems, you will be expected to report this to the 
doctor. 
Can you withdraw from this study after it starts?
Your participation in this study is entirely voluntary and you are also free to decide to 
withdraw permission to participate in this study. If you do so, this will not affect your usual 
treatment at this hospital in any way
What will happen if you develop any study related injury?
This is an observational study therefore we do not expect any injury to happen apart from 
prostate biopsy related complications. But if you do develop any side effects or problems 
due to the study, these will be treated at no cost to you. We are unable to provide any 
monetary compensation, however. 
Will your personal details be kept confidential?
The results of this study will be published in a medical journal but you will not be identified 
by name in any publication or presentation of results. However, your medical notes may be 
reviewed by people associated with the study, without your additional permission, should 
you decide to participate in this study. 
If you have any further questions, please ask Dr. Feroz Mohd Khan (Tel: 0416 2282455/ 
2282011).
CONSENT TO TAKE PART IN A CLINICAL TRIAL
Study Title: To Evaluate the complications of TRUS guided prostate biopsy
Study Number:
Participant’s name:
Date of Birth / Age (in years):
I_____________________________________________________________
___________, son/daughter of  ___________________________________
(Please tick boxes)
Declare that I have read the information sheet provide to me regarding this study and have 
clarified any doubts that I had. [ ]
I also understand that my participation in this study is entirely voluntary and that I am free 
to withdraw permission to continue to participate at any time without affecting my usual 
treatment or my legal rights [ ]
I understand that I will receive free treatment for any study related injury or adverse event 
but I will not receive any other financial compensation [ ]
I understand that the study staff and institutional ethics committee members will not need 
my permission to look at my health records even if I withdraw from the trial. I agree to this 
access [ ] 
I understand that my identity will not be revealed in any information released to third 
parties or published [ ] 
I voluntarily agree to take part in this study [ ]
Name:
Signature: OR          Left Thumb Impression:
                                    
Date:
Name & Signature of Principal Investigator/Co-investigator:
